- Home
- CLNN
CLNN
Clene Inc.
as 12-20-2024 4:00pm EST
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 43.0M | IPO Year: | N/A |
| Target Price: | $55.25 | AVG Volume (30 days): | 114.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.82 - $11.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | $421,000 | Revenue Growth: | -41.36% |
| Revenue Growth (this year): | -43.39% | Revenue Growth (next year): | -21.95% |
Latest Clene Inc. News
CLNN Breaking Stock News: Dive into CLNN Ticker-Specific Updates for Smart Investing
NewMediaWire
2 days ago
IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments
GlobeNewswire
3 days ago
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
NewMediaWire
11 days ago
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway
GlobeNewswire
12 days ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
TipRanks
a month ago
Clene price target lowered to $83 from $86 at Canaccord
GlobeNewswire
a month ago
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights
NewMediaWire
2 months ago
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership
NewMediaWire
2 months ago
IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences
Compare CLNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLNN Clene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.